摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3'-trimethylene-2,2'-bipyridine | 97919-83-0

中文名称
——
中文别名
——
英文名称
3,3'-trimethylene-2,2'-bipyridine
英文别名
3,15-Diazatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene
3,3'-trimethylene-2,2'-bipyridine化学式
CAS
97919-83-0
化学式
C13H12N2
mdl
——
分子量
196.252
InChiKey
YEYSYOWRLMCHBB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    140-141 °C
  • 沸点:
    402.1±20.0 °C(Predicted)
  • 密度:
    1.152±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Drug conjugates
    申请人:Ojima Iwao
    公开号:US20050232928A1
    公开(公告)日:2005-10-20
    A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NR a or NR b ; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R 1 nor R 1 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and R a , R b , R 1 , R 2 , R 3 , R 4 are as defined in the specification.
    具有Y-A-Z分子式的化合物,其中:A是一个5、6或7成员环,可以是单环的,也可以与1至3个额外的4至8成员环融合;其中环A和额外融合的环独立地可以是碳环或杂环,饱和或不饱和,不饱和环可以是芳香的或非芳香的;其中Y和Z是环A上相邻位置的取代基;Y代表:Z代表:X和E代表O、S或NRa或NRb;a、b、c、d、e和f中的每一个独立地代表0或1;a+c等于0、1或2;b+d等于0、1或2;a+b+c+d+e+f等于1、2或3;条件是当f为1时,d为1,当d为0时,f为0;当e和b都为0时,R1和R1都不是氯或溴;v代表0或1,条件是当v为0时,J为氢、金属离子或季铵离子;X为O且G为H;G为氢、金属离子、季铵离子、低碳基,或由药用活性化学化合物或其前体组成;或者X-G代表一个羰基活化基团;J为低碳基、芳基、杂环基、ω-羟基羰基-(低碳基)、ω-(低烷氧基)羰基-(低碳基)、ω-(X-G)-羰基-(低碳基)基团,或由特异结合剂组成;而Ra、Rb、R1、R2、R3、R4如规范中所定义。
  • DRUG CONJUGATES
    申请人:Ojima Iwao
    公开号:US20080139815A1
    公开(公告)日:2008-06-12
    A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NR a or NR b ; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R 1 nor R 2 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion, and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and R a , R b , R 1 , R 2 , R 3 , R 4 are as defined in the specification.
    化合物的化学式为Y-A-Z,其中:A是一个5、6或7个成员环,可以是单环或与1到3个其他4到8个成员环融合;其中,环A和独立的融合环均为碳环或杂环,饱和或不饱和,不饱和环为芳香或非芳香;Y和Z是环A上相邻位置的取代基;Y代表:Z代表:X和E代表O、S或NRa或NRb;a、b、c、d、e和f中的每一个都独立地表示0或1;a+c等于0、1或2;b+d等于0、1或2;a+b+c+d+e+f等于1、2或3;但当f为1时,则d为1,当d为0时,则f为0;当e和b都为0时,则R1和R2均不是氯或溴;v表示0或1,但当v为0时,则J为氢、金属离子或季铵离子,而X为O且G为H;G可以是氢、金属离子、季铵离子、低碳基或由药物活性化合物或其前体组成;或者X-G表示一个羰基活化基团;J是低碳基、芳基、杂环基、ω-羟基羧酸-(低碳基)、ω-(低烷氧基)羧酸-(低碳基)、ω-(X-G)-羧酸-(低碳基)基团,或由特定结合剂组成;Ra、Rb、R1、R2、R3、R4如说明书所定义。
  • BENZO[k]FLUORANTHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE CONTAINING THE SAME
    申请人:Ito Hirokatsu
    公开号:US20120211743A1
    公开(公告)日:2012-08-23
    A benzo[k]fluoranthene derivative represented by the following formula (1): wherein R 1 to R 12 are as defined in the specification. The benzo[k]fluoranthene derivative represented by the formula (1) reduces a driving voltage of an organic electroluminescence device and makes it possible to realize light emission with high efficiency and long lifetime.
    一种由下式(1)表示的苯并[k]芴衍生物:其中R1至R12如规范中所定义。由式(1)表示的苯并[k]芴衍生物降低了有机电致发光装置的驱动电压,使其能够实现高效率和长寿命的光发射。
  • BENZO[K]FLUORANTHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT CONTAINING SAME
    申请人:Idemitsu Kosan Co., Ltd.
    公开号:EP2626346A1
    公开(公告)日:2013-08-14
    A benzo[k]fluoranthene derivative represented by the following formula (1): wherein R1 to R12 are as defined in the specification. The benzo[k]fluoranthene derivative represented by the formula (1) reduces a driving voltage of an organic electroluminescence device and makes it possible to realize light emission with high efficiency and long lifetime.
    下式(1)所代表的苯并[k]荧蒽衍生物: 其中 R1 至 R12 如说明书中所定义。由式(1)表示的苯并[k]荧蒽衍生物可降低有机电致发光器件的驱动电压,实现高效率和长寿命发光。
  • Thummel, Randolph P.; Lefoulon, Francois; Korp, James D., Inorganic Chemistry, 1987, vol. 26, # 15, p. 2370 - 2376
    作者:Thummel, Randolph P.、Lefoulon, Francois、Korp, James D.
    DOI:——
    日期:——
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-